Centocor CentoRx
Executive Summary
PLA for CentoRx for the prevention of coronary artery blockages caused by blood clots in patients who have undergone high-risk angioplasty has been submitted to FDA, the biotech firm announces Dec. 15. Eli Lilly has worldwide marketing rights to the drug.